76 results
6-K
EX-99.2
ENLV
Enlivex Therapeutics Ltd
11 Apr 24
Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis
8:13am
, responsible for the global clinical development of sorafenib (Nexavar ® ) at Bayer. Former CEO of PROLOR Biotech. Founding team and Director of R&D
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
29 Mar 24
Report of Foreign Private Issuer
4:30pm
Control—Integrated Framework (2013) issued by COSO.
Basis for Opinion
The Company’s management is responsible for these financial statements
6-K
EX-99.1
gpf8qooli5 tc4nnlu
31 Mar 23
Report of Foreign Private Issuer
4:30pm
6-K
EX-99.1
r9a374oh5mlbb9myc
5 Oct 22
Notice of Annual General Meeting of Shareholders
3:00pm
UPLOAD
vjeca63w 8zli8
2 May 22
Letter from SEC
12:00am
6-K
EX-99.1
qf4rs 1xexqr
30 Sep 21
Annual and Extraordinary General Meeting of Shareholders
8:01am
6-K
EX-99.1
bywysmxryldgv
2 Aug 21
Enlivex Hires Biotech Industry Veteran Tzvi Palash to Lead the Design and Construction of its New cGMP Allocetra Manufacturing Plant
8:02am
6-K
EX-10.1
7nf3yfux abumy
12 Feb 21
Enlivex Announces Closing of Previously Announced Bought Deal Offering of Approximately $46.0 Million Ordinary Shares
5:17pm
424B5
syz9n7
10 Feb 21
Prospectus supplement for primary offering
5:22pm
424B5
ju7dslnqz
9 Feb 21
Prospectus supplement for primary offering
4:56pm
6-K
EX-99.1
rt8jvkcd3i3ph
17 Nov 20
Enlivex Appoints Former ArQule, Inc. Executive Dr. Brian Schwartz to the Company’s Board of Directors
8:18am